For a growing number of diseases, combination therapies are being employed, due in part to their superior efficacy compared to monotherapies. These therapies utilize different mechanisms of action for each agent employed, thereby acting on multiple molecular targets or intervening at two or more sites in disease-specific pathways (to minimize drug resistance) to more effectively prevent disease progression and perhaps reduce toxicity (e.g. combination drugs used at lower doses). There are a number of publications that cite the benefits of combination therapy over monontherapy, but this type of treatment often comes with increased toxicity.[1,2] While combining multiple agents is often beneficial for disease progression, the adverse effects may be unexpected and difficult to predict.
ReferencesFOR COMBINATION THERAPIES
ReachBio Research Labs can perform tests using combinations of compounds on either normal or diseased bone marrow to assess additive or synergistic toxicity. Additionally, a protective effect by one compound can also be detected using these assays.
1. R.Z. Orlowski et. al.
J. Clin. Oncol. 2007 (Sept 1); 25(25) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Discuss with our CSO how ReachBio Research Labs can address your needs to investigate potential hemotoxic liabilities of your proposed drug combinations.
2. C.K. Min et. al.,
Jpn J Clin. Oncol. 2007 (Dec); 37(12): 961-8. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.